These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17529866)

  • 1. Use of combination vaccines is associated with improved coverage rates.
    Marshall GS; Happe LE; Lunacsek OE; Szymanski MD; Woods CR; Zahn M; Russell A
    Pediatr Infect Dis J; 2007 Jun; 26(6):496-500. PubMed ID: 17529866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population.
    Happe LE; Lunacsek OE; Kruzikas DT; Marshall GS
    Pediatr Infect Dis J; 2009 Feb; 28(2):98-101. PubMed ID: 19148039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination vaccine use and vaccination quality in a managed care population.
    Happe LE; Lunacsek OE; Marshall GS; Lewis T; Spencer S
    Am J Manag Care; 2007 Sep; 13(9):506-12. PubMed ID: 17803364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
    J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
    Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
    Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
    Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of Monovalent Vaccine Administration in Infants Receiving DTaP-based Combination Vaccines in the United States.
    Marshall GS; Petigara T; Liu Z; Wolfson L; Johnson D; Goveia MG; Chen YT
    Pediatr Infect Dis J; 2022 Sep; 41(9):775-781. PubMed ID: 35763699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States.
    Dennehy PH; Bertrand HR; Silas PE; Damaso S; Friedland LR; Abu-Elyazeed R
    Pediatrics; 2008 Nov; 122(5):e1062-6. PubMed ID: 18977955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely.
    Omeñaca F; Garcia-Sicilia J; Boceta R; Sistiaga-Hernando A; García-Corbeira P
    Pediatr Infect Dis J; 2007 Sep; 26(9):824-9. PubMed ID: 17721379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a new combined vaccine in pediatric practices.
    Freed GL; Cowan AE; Clark SJ; Santoli J; Bradley J
    Pediatrics; 2006 Aug; 118(2):e251-7. PubMed ID: 16831895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of DTaP-IPV-HB vaccine on use of health services for young infants.
    Thompson LA; Irigoyen M; Matiz LA; LaRussa PS; Chen S; Chimkin F
    Pediatr Infect Dis J; 2006 Sep; 25(9):826-31. PubMed ID: 16940842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age.
    Pietrzyk JJ; Wysocki J; Pejcz J; Galaj A; Majda-Stanislawska E; Käyhty H; Thierry-Carstensen B; Jensen AM
    Vaccine; 2008 Sep; 26(41):5296-303. PubMed ID: 18675870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated polio vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Partridge S; Alvey J; Bernstein H; Blatter M; Bottenfield G; Guerrero J; Senders SD; Schuerman L; Cheuvart B; Holmes SJ
    Vaccine; 2007 Feb; 25(10):1806-13. PubMed ID: 17240493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2003 Mar; 52(10):203-4. PubMed ID: 12653460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age.
    Scheifele DW; Halperin SA; Smith B; Ochnio J; Meloff K; Duarte-Monteiro D
    Vaccine; 2006 Mar; 24(12):2057-64. PubMed ID: 16356598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.